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Psoriasis is a chronic inflammatory skin disease, which is associated with systemic inflammation and comorbidities, such as
psoriatic arthritis and cardiovascular diseases. The autoimmune nature of psoriasis has been established only recently, conferring
a central role to epidermal CD8 T cells recognizing self-epitopes in the initial phase of the disease. Different subsets of helper cells
have also been reported as key players in the psoriasis pathogenesis. Here, we reviewed the knowledge on the role of each subset
in the psoriatic cascade and in the different clinical manifestations of the disease. We will discuss the role of Th1 and Th17 cells in
the initiation and in the amplification phase of cutaneous inflammation. Moreover, we will discuss the recently proposed role of
tissue resident Th22 cells in disease memory in sites of recurrent psoriasis and the possible involvement of Th9 cells. Finally, we
will discuss the hypothesis of a link between T helper cell subsets recirculating from the skin and the systemic manifestations of
psoriasis.
1. Introduction
Psoriasis is a chronically relapsing hyperproliferative skin
inflammation affecting about 2% of the population world-
wide and is among the most frequent T cell-mediated
disorders. Plaque psoriasis, also known as psoriasis vulgaris,
is the commonest form of the disease, accounting for almost
90% of psoriatic patients [1, 2].
Histologically, psoriasis is characterized by three prin-
cipal features: epidermal hyperplasia, leukocyte infiltrates,
and an increased number of tortuous and leaky vessels in
the dermis resembling the regenerative maturation observed
during wound repair. In recent studies, we and others have
reported the enhanced presence of lymphoid aggregates in
the dermis of psoriatic plaques as compared to normal skin
[3, 4].
About 30% of patients with psoriasis also develop pso-
riatic arthritis, characterized by synovitis, enthesitis, and
dactylitis. Besides skin and joint inflammation there is evi-
dence that psoriasis is associated with important systemic
manifestations andwith comorbidities such as cardiovascular
disorders, metabolic syndrome, and Crohn’s disease [5–7].
Many advances have been made in the last decades
in the understanding of psoriasis pathogenesis leading to
the identification of the T cell subsets that play a role in
establishing inflammation in psoriatic skin lesions.
Different subsets of T cells may have a different hierar-
chical role in the pathogenesis of the disease underlining the
importance of distinguishing T cell subpopulations involved
in the initiation phase of the disease from those acting as
downstream effectors amplifying inflammation in psoriatic
plaques possibly accounting for the extent of the clinical
manifestations [2, 8].
The autoimmune nature of psoriasis has been established
only recently by the discovery of the role of cathelicidin
(LL37), keratinocyte-derived antimicrobial peptide, as an
autoantigen for both CD8 and CD4 autoreactive T cells in
psoriasis patients.
In addition, a second antigen, ADAMTS-like protein
5 (ADAMTSL5), which is produced by melanocytes, has
also been identified as an autoantigen recognized by IL-17-
producing CD8 T cells, restricted by HLA-C∗06:02 [9, 10].
These two reports together with early studies on self-
reactive CD8 T cells strongly support that CD8 T cells
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represent the autoimmune core of the disease driving the
initial phase of psoriasis and repository of specific disease
memory [11–15].
As regards T helper cells, in the last several years, different
subsets have been described as critical factors in psoriasis
pathogenesis. Specifically, Th1 cells that were originally con-
sidered as the main player in psoriasis pathogenesis have
been proposed to be actually more relevant in early stages
of the disease, upstream of the IL-17 driven proinflammatory
loop. At the same time, genetic association studies together
with human and mouse experimental data and the results
of clinical trials have shifted the attention to IL-23/Th17 axis
controlling mainly the proinflammatory loop in psoriatic
plaques which involves keratinocytes, dendritic cells, and
T cells [16, 17]. It is important to mention that 𝛾𝛿 T cells
also play a major role in the production of IL-17 and in the
maintenance of inflammation in psoriatic plaques [2, 18–22].
More recently, the role of tissue resident Th22 cells in
psoriasis has been enlightened and a role for Th9 cells has
been proposed.
We have recently reported that CCR4+ CD4+ T cells
are increased in the circulation of patients with psoriasis
proportionally with the increased severity of the cutaneous
manifestations of the disease expressed as PASI (Psoriasis
Area and Severity Index) score. This links CD4+ T helper
cells recirculating between skin and blood with the clinical
manifestations of psoriasis.
2. Th17 and Th1: Key Player in
Psoriasis Pathogenesis
Psoriasis was originally considered a Th1-mediated skin
disease, whereas, in recent years, the focus has been shifted
to Th17 cells and to other IL-17-producing cell types, notably
𝛾𝛿 T cells and CD8 T cells [23–27].
Th17 cytokines, in particular interleukin-17A (IL-17A),
have been shown to have a pivotal role in sustaining inflam-
mation in psoriatic plaques. The number of IL-17-producing
CD4+ T cells has been observed to be much higher in
psoriatic skin lesions than in healthy skin [28–30]. Th17 cells
are crucial for the secretion of IL-17A, IL-17F, IL-22, and IL-9,
which promote the inflammatory response of keratinocytes
as indicated by studies in cultured human keratinocytes and
in an IL-17-treated reconstituted human epidermis model
[31]. Antimicrobial peptides, cytokines, and chemokines such
as CCL20 and CXCL1, CXCL3, and CXCL8 are part of the
IL-17-induced signature in keratinocytes and play a crucial
role in amplifying the immune response in psoriatic plaques
[31–35]. Therefore, activated Th17 cells can enhance the
inflammatory response of keratinocytes by creating a positive
feedback loop around the IL-23/Th17 axis [16].
The key role of this axis in psoriasis pathogenesis is
strongly supported by the association between IL-23R, IL-
12B, and IL-23A gene variants and psoriasis susceptibility
[36]. Definitive evidence finally emerged from the results of
clinical trials with anti-IL-17 antibody showing very rapid and
highly effective outcome in patients with cutaneous psoriasis.
In these trials, treatments with secukinumab and ixekizumab,
anti-IL-17 monoclonal antibodies, and brodalumab, an IL-
17RA receptor antagonist, indicate IL-17 inhibitors as supe-
rior in psoriasis efficacy compared to TNF𝛼 inhibitors and
IL-12/IL-23 inhibitors with very few serious adverse events
[37–43]. The rapid and highly effective results of anti-IL-17-
based therapy strongly support the concept of a role for IL-
17 as a pivotal amplifying effector mechanism in psoriasis
determining the extent of the cutaneousmanifestations of the
disease [44].
As a consequence of the strong evidence of the central role
of IL-17-producing cells, the relevance of Th1 cells and IFN𝛾
has become less clear. In lesional skin of psoriasis patientsTh1
cells and IFN𝛾 levels are clearly increased [45, 46]. Results
from a study byKryczek et al. have suggested that IFN𝛾 exerts
one of its main effects in psoriasis pathogenesis upstream of
IL-17 in the psoriatic cascade. According to this view IFN𝛾
produced by Th1 and other cells would program myeloid
dendritic cells to produce CCL20 ligand of CCR6 and to
secrete IL-23. This in turn would favor the recruitment and
expansion of IL-17-producing cells. IFN𝛾 mRNA is indeed
markedly upregulated in psoriatic plaques and noticeably
genes which in keratinocytes are induced by IFN𝛾, such
as CXCL9, CXCL10, and CXCL11, are also upregulated in
psoriatic lesions.This evidence could point towards a role for
IFN𝛾 in mediating further recruitment of CXCR3+ Th1 and
CD8 T cells in psoriatic plaques [35, 47, 48]. This is in line
with our recent data indicating recruitment of CCR5+ IFN𝛾-
producing CD4+ T cells to the psoriatic plaques at advanced
stages of the disease [49].
On the other hand, in mouse models of autoimmune dis-
eases such as Collagen-Induced Arthritis (CIA) and induced
experimental autoimmune encephalomyelitis (EAE), it has
been shown that IFN𝛾 suppresses the production of IL-17
and, in the case of CIA, it exerts a protective effect against
the disease development [50–52].
Moreover, in a small pilot study, humanized anti-IFN𝛾
antibody has been used in the treatment of psoriasis showing
only a minor therapeutic effect [53, 54].
These controversial findings underline a complex inter-
play betweenTh1 andTh17 cells in the pathogenesis of psori-
asis and despite the marked enhancement of both cytokines
in psoriatic skin lesions the understanding of their relative
role in disease pathogenesis needs to be further clarified.
3. Th22
Th22 cells are important for skin homeostasis and in inflam-
mation. Similarly to Th17, they express IL-23R but mainly
produce IL-22 in the absence of IL-17 [55, 56]. In humans,
Th22 localizes to the skin and can express IL-22, TNF𝛼,
and IL-13 [57]. In human skin, the IL-22R1 subunit of the
IL-22 receptor complex is constitutively expressed mainly
by nonhematopoietic tissue resident cells; it was observed
in keratinocytes and was upregulated by IFN𝛾 [58]. In
psoriatic patients elevated IL-22 plasma levels have been
detected, which correlated with the disease severity. The
role of IL-22 in psoriasis pathogenesis has been linked to
keratinocyte activation and to the formation of epidermal
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acanthosis, a prominent morphologic feature of psoriasis [35,
59]. IL-22 indeed regulates keratinocyte function in multiple
ways. In particular, it favors the formation of a biological
barrier of the skin through the induction of antimicrobial
proteins in keratinocytes, it inhibits terminal keratinocyte
differentiation, it induces the production of matrix metallo-
proteinases 1 and 3 linked to tissue degradation, and it recruits
neutrophils through the induction of chemokine production
[59]. Together with other cytokines, such as TNF𝛼, IL-17,
and IL-20, IL-22 therefore takes part in the formation of
the cytokine network that orchestrates the progression of the
different pathogenic features of psoriasis [60].
An important study has reported that epidermal Th22
cells in resolved psoriatic plaques were still functional after
several years of disease remission underlining a role for
tissue resident Th22 in psoriasis pathogenesis and in disease
memory in sites of recurrent psoriasis [11].
In mouse imiquimodmodels of psoriasis, IL-22-deficient
mice have an evident decrease in the formation of psoriasis-
like lesions, in particular pustule formation and acantho-
sis. Moreover, using an autoimmune psoriasis model, mice
treated with IL-22 neutralizing antibody demonstrated either
no development or extremely mild development of psoriasis,
which suggests that IL-22 antagonismmay lead to a therapeu-
tic approach [58, 59, 61].
4. Th9 and Pathogenic T Helper Subsets
Th9 cells represent a skin-tropic subpopulation which is
present both in healthy and in diseased human skin [62, 63].
Th9 cells have been detected within psoriatic skin lesions as
well as in other inflammatory skin disorders such as atopic
dermatitis. In psoriatic skin lesions, the number of IL-9-
producing cells was found to be higher compared to healthy
skin, and gene expression analysis indicates significantly
augmented IL9 expression as compared to normal skin from
healthy subject [49, 62]. Th9 cells are found primarily among
the CLA+ skin-homing T cell population. CLA+ Th9 cells
upon activation can rapidly and transiently produce IL-9,
which in turn exerts an autocrine effect by inducing further
IL-9 production and a paracrine effect by inducing IFN𝛾,
IL-17, and IL-13 production by CLA+ Th1, Th2, and Th17
cells. The ability of Th9 cells to enhance the production
of inflammatory cytokines from other T cell subsets and
their increased presence in psoriatic skin lesions suggest that
Th9 cells may also participate in initiating and maintaining
cutaneous inflammation [62].
Finally, a role for Th21 has been proposed in psoriasis
pathogenesis [64]. IL-21 is indeed expressed at higher level
in psoriatic skin lesions, where it is mainly produced by
infiltrating CD4+ T cells and by NK cells. As IL-21R is
expressed by both T cells and keratinocytes, it has been
proposed that IL-21 could play a role in disease pathogenesis
either by exerting a mitogenic effect on keratinocytes thus
acting in synergy with factors such as IL-22 or by expanding
other pathogenic T helper cell subsets. Noticeably, IL-21 was
also found to be expressed by T cells coexpressing IFN𝛾
or IL-17. This evidence brings us to the concept of specific
pathogenic T helper subsets in the pathogenesis of psoriasis.
Pathogenic T helper cells are now defined as subsets of T cells
that develop from classical Th1/Th2 and Th17 subsets under
specific conditions. They secrete a distinguishing cytokine
profile and possibly exert a role in the induction of the
diseases [65]. In psoriatic skin lesions, a subset of cells
coexpressing IL-17 and IFN𝛾 has been described, which can
possibly fall into the recently defined categories of non-
classic Th1 cells or Th1∗ cells [27, 66–68]. These cells have
more aggressive inflammatory phenotype and they may be
regarded as an example of disease-inducing T helper subset.
5. Emerging Role of Recirculating
T Helper Cells in Different Clinical
Manifestations of Psoriasis
Besides skin and joint inflammation, there is now evidence
that psoriasis is associated with important systemic manifes-
tations and comorbidities such as cardiovascular disorders,
metabolic syndrome, and Crohn’s disease [5, 6].
As an explanation to the systemic manifestation of the
psoriatic diseases, the concept of “psoriatic march” has been
introduced, which views psoriasis as a state of systemic
inflammation that leads to the involvement of other organs
besides skin through the systemic circulation [6, 69].
In this process, soluble mediators of systemic inflam-
mation have been identified and include serum TNF𝛼,
vascular endothelial growth factor (VEGF), IL-12, monocyte
chemotactic protein-1 (MCP-1), S100A8/A9, and importantly
systemic levels of circulating IL-17A of particular relevance
for cardiovascular comorbidities [5].
Psoriasis patients with moderate-to-severe disease have
significantly elevated serum IL-17A levels [30, 70], which
appear to be associated with higher risk of developing car-
diovascular complications including stroke and myocardial
infarction. In human atherosclerotic lesions, IL-17A/IL-17F
levels are increased at each stage of plaque development and
in advanced coronary plaques CD4+ T cells expressing both
IFN𝛾 and IL-17 were also detected [71, 72].
Despite this evidence, the cell trafficking events represent-
ing the pathogenic link between the skin manifestations and
systemic inflammation and development of comorbidities are
still largely unknown.
In psoriasis patients, we have previously described the
presence of dermal lymphoid aggregates mainly composed
of CD4+ T cells and myeloid dendritic cells. CD4+ T cells in
these aggregates expressed CCR7 and the axis CCR7/CCL19
in psoriatic skin lesions was shown to play a critical role in
the disease pathogenesis and in disease remission induced by
TNF-blockers [4].
In a Kaede transgenic mouse model, Luster and cowork-
ers have demonstrated that CD4 memory T cells can exit
from the skin in aCCR7-dependentmanner.A subpopulation
of recirculating memory CD4+ T cells in peripheral blood
with a CCR7+CD69−CD103+/−CCR4+/− phenotype has been
identified, which can enter the circulation and maintains the
ability to migrate into normal skin [73].
4 Journal of Immunology Research
It is therefore possible to hypothesize that human diseases
of barrier tissues, such as psoriasis, may involve a similar
dynamic balance between tissue resident memory T cells and
the recirculating pool [74].
Our recent data indicate that specific subsets of memory
T cells are involved in the clinicalmanifestations of cutaneous
psoriasis and in systemic inflammation. In particular, we
identified that CCR5+ CD4+ T cells are inversely associated
with the extent of the cutaneous manifestations, suggesting
a contribution in the formation of the psoriatic plaque [49].
By contrast, we observed increased circulating percentage of
CCR4+ T cells in psoriasis patients. CCR4+ CD4+ T cells
with TEM and Teff phenotype in the circulation correlated
positively with the severity of the cutaneous disease; however,
we did not find any significant correlation with systemic
inflammation.
CCR4 has been defined as a skin-homing receptor that
is upregulated by memory T cells which have been primed
in skin draining lymph nodes. T cells expressing CCR4 can
therefore relocalize to the skin when inflammatory signals
induce the expression of its ligand CCL17 [75–77]. These
observations suggest that CCR4+CD4+ T cells may represent
a subset of cells which recirculates from the skin with the
ability to relocalize to the skin compartment upon antigen
reexposure or expression of inflammatory signals [76, 77].
By contrast, we found that CCR4+ CD8+ CD103+ Teff
cells in the circulation highly correlatedwith systemic inflam-
mation and with PASI score, thus representing a possible link
between the severity of the cutaneous manifestations of the
disease and systemic inflammation.
In the CD4 compartment, we found that CCR6+
CD4+ TEM cells correlated with systemic inflammation mea-
sured as serum level of C-reactive protein (unpublished data),
in line with the increase of IL-17A in serum of patients with
severe psoriasis and with its association with cardiovascular
diseases.
This initial evidence supports that T helper cell recircula-
tion from the skin can play a role in either the amplification
of the cutaneous manifestations or in the development of
comorbidities associated with psoriasis. Further investiga-
tions could possibly provide additional information elucidat-
ing the connection between T cells responses arising in the
skin and the systemic manifestations of psoriasis.
6. Conclusions
Different subsets of helper cells have been reported to
contribute to the pathogenesis of psoriasis. However, it is
important to define for each subset the role in the psoriatic
cascade and in the clinical manifestations of the disease. In
particular, IL-23/Th17 axis was shown to be central in ampli-
fication of inflammation and cutaneous manifestations of
psoriasis as supported by the high therapeutic efficacy of anti-
IL-17 antibodies used in clinical trials. By contrast, Th1 cells
likely participate in earlier stage of psoriasis pathogenesis by
inducing CCL20 and IL-23 production by myeloid dendritic
cells, thus playing a role upstream of the proinflammatory
cascade controlled by IL-23/Th17 axis.
Tissue resident Th22 together with CD8 Tc17 cells have
been proposed as repository of disease memory in sites
of recurrent psoriasis and because of the action of IL-22
on keratinocytes, they are linked to the most prominent
histological features of psoriasis. Recently, IL-9-producing
Th9 cells have been found to play significant roles in the
pathogenesis. Finally, there is an emerging a role for CD4
T cells recirculating between skin and blood in the clinical
manifestations of psoriasis and the associated comorbidities.
In particular, possible roles for CCR4+ CD4 and CD8 T cells
in amplification of skin and in systemic inflammation have
been indicated, respectively.
Further investigations are needed to elucidate the con-
nection between T cells responses arising in the skin and the
comorbidities associated with psoriasis.
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